PROCEPT BioRobotics (NASDAQ: PRCT) is scheduled to announce its fourth-quarter earnings for the 2025 fiscal year on February 24, 2026, after the market closes. Analysts anticipate that the company will report a loss of ($0.32) per share, alongside projected revenues of $93.704 million for the quarter. This earnings call is expected to shed light on the company’s financial performance and growth strategies.
Current Stock Performance and Financial Ratios
As of Tuesday, shares of PROCEPT BioRobotics opened at $27.79. The company currently exhibits a quick ratio of 7.20 and a current ratio of 8.44, indicating strong liquidity. The debt-to-equity ratio stands at 0.14, suggesting a conservative approach to leveraging. PROCEPT BioRobotics has a market capitalization of $1.55 billion, a price-to-earnings ratio of -18.16, and a beta of 0.99. Over the past year, the stock has seen a low of $26.66 and a high of $70.80, highlighting volatility in its trading history. The 50-day simple moving average is $31.48, while the 200-day moving average is $34.50.
Analyst Ratings and Price Targets
Several analysts have recently provided updates on PROCEPT BioRobotics. On November 5, 2025, Leerink Partners reaffirmed an “outperform” rating with a price target of $55.00. Conversely, Wells Fargo & Company lowered its price target from $58.00 to $51.00 while maintaining an “overweight” rating. Meanwhile, Wall Street Zen upgraded its rating from “sell” to “hold” on January 10, 2026.
Additionally, TD Cowen reduced its price objective from $85.00 to $50.00, maintaining a “buy” rating. UBS Group initiated coverage on PROCEPT BioRobotics on December 12, 2025, assigning a “buy” rating and a target price of $62.00. Overall, one research analyst has designated the stock with a “Strong Buy” rating, while nine others have rated it as a “Buy.” The stock has a consensus rating of “Moderate Buy” and a price target of $53.40, according to MarketBeat.
Institutional Investment Trends
Institutional investors have shown significant interest in PROCEPT BioRobotics. AQR Capital Management LLC increased its stake by 7.3% in the first quarter, now holding 18,892 shares valued at $1,101,000. UBS AM, a distinct business unit of UBS Asset Management Americas LLC, also raised its position by 9.9%, totaling 153,158 shares worth $8,923,000 after acquiring an additional 13,767 shares.
Furthermore, Intech Investment Management LLC expanded its stake by 54.4%, owning 28,389 shares valued at $1,654,000. Prudential Financial Inc. doubled its stake during the second quarter, now holding 6,815 shares worth $393,000. State Street Corp also increased its holdings by 6.9%, owning 1,269,110 shares valued at $73,101,000. In total, institutional investors and hedge funds control approximately 89.46% of the company’s stock.
Company Overview and Future Prospects
PROCEPT BioRobotics is a medical device company focused on developing robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s innovative technology utilizes precision robotics and real-time imaging to perform minimally invasive procedures, which are designed to enhance patient recovery times and improve clinical outcomes compared to traditional surgical methods. The flagship product, the AquaBeam Robotic System, employs a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.
As the earnings announcement approaches, investors and analysts are keenly awaiting insights into PROCEPT BioRobotics’ financial health and strategic direction for the upcoming year.
